Literature DB >> 25306380

Treating kleptomania: cross-cultural adaptation of the Kleptomania Symptom Assessment Scale and assessment of an outpatient program.

Aparecida Rangon Christianini1, Maria Aparecida Conti2, Norman Hearst3, Táki Athanássios Cordás4, Cristiano Nabuco de Abreu5, Hermano Tavares5.   

Abstract

BACKGROUND: Kleptomania is characterized by repetitive stealing and has severe consequences for patients. Stigma, a lack of standardized therapy and a limited number of assessment tools hinder advances in treatment. This study provides preliminary data on the Portuguese-language version of the Kleptomania Symptom Assessment Scale (P-K-SAS) and preliminary data on an outpatient program.
METHODS: Experts in the field analyzed an initial P-K-SAS version, produced through translation/back-translation, in order to arrive at a final version. Eight patients currently on cognitive-behavioral therapy (CBT) and 10 patients under maintenance CBT were initially assessed, then re-assessed 6months later.
RESULTS: The mean P-K-SAS score was higher among patients initiating CBT than among those under maintenance CBT (21.1±8.0 vs. 11.3±7.5; Mann-Whitney U=15.0, P=.024). The final version of the P-K-SAS presented excellent reliability (Cronbach's alpha=0.980; inter-item correlation, 0.638-0.907).
CONCLUSIONS: The P-K-SAS presented solid psychometrics and seems ready for use in assessing the effectiveness of treatments for kleptomania. The findings suggest that kleptomania patients need follow-up treatment that goes beyond the traditional 12-session structure.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2014        PMID: 25306380     DOI: 10.1016/j.comppsych.2014.09.013

Source DB:  PubMed          Journal:  Compr Psychiatry        ISSN: 0010-440X            Impact factor:   3.735


  1 in total

1.  Impairments of kleptomania: what are they?

Authors:  Hyoun S Kim; Aparecida Rangon Christianini; David C Hodgins; Hermano Tavares
Journal:  Braz J Psychiatry       Date:  2017 Jul-Sep       Impact factor: 2.697

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.